Advertisement
The Medicine Maker / Issues / 2016 / Articles / Oct / The Fight for Transparency
Business & Regulation Regulation & Standards Business & Trends

The Fight for Transparency

The EMA says “yes” to transparency, but some pharma companies have other ideas

By James Strachan 10/20/2016 1 min read

Share

Advertisement

Recommended

Advertisement

Related Content

What Trump’s Latest Moves Mean for the Industry
Interviews Bioprocessing Business & Trends
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Regulators Target Ebola
Regulation & Standards Business & Trends
Regulators Target Ebola

December 1, 2014

0 min read

Will FDA fast review and voucher incentives make a difference?

Safety First - Sizing Up Biologics Side Effects
Regulation & Standards Business & Trends
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

United Science Stands
Small Molecules Regulation & Standards Business & Trends
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

Advertisement